The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications

References

• Lipinski S, Bremer L, Lammers T, et al. Coagulation and inflammation. Molecular insights and diagnostic implications. Hamostaseologie 2011;31:94-102
   PubMed Web of Science ®Google Scholar
• de Maat S, Tersteeg C, Herczenik E, et al. Tracking down contact activation - from coagulation in vitro to inflammation in vivo. Int J Lab Hematol 2014;36:374-81
   PubMed Web of Science ®Google Scholar
• Koutroumpakis EI, Tsiolakidou G, Koutroubakis IE. Risk of venous thromboembolism in patients with inflammatory bowel disease. Semin Thromb Hemost 2013;39:461-8
   PubMed Web of Science ®Google Scholar
• Owczarek D, Cibor D, Głowacki MK, et al. Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol 2014;20:53-63
   PubMed Web of Science ®Google Scholar
• Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol 2014;20:4857-72
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: canadian association of gastroenterology. Gastroenterology 2014;146:835-48
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272-80
   PubMed Web of Science ®Google Scholar
• Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010;139:779-87. e1
   PubMed Web of Science ®Google Scholar
• Anthoni C, Russell J, Wood KC, et al. Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis. J Exp Med 2007;204:1595-601
   PubMed Web of Science ®Google Scholar
• Yoshida H, Russell J, Senchenkova EY, et al. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 2010;177:2774-81
   PubMed Web of Science ®Google Scholar
• Kohoutova D, Moravkova P, Kruzliak P, et al. Thromboembolic complications in inflammatory bowel disease. J Thromb Thrombolysis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Haraldsen G, Rugtveit J, Kvale D, et al. Isolation and long term culture of human intestinal microvascular endothelial cells. Gut 1995;37:225-34
   PubMed Web of Science ®Google Scholar
• Nilsen EM, Johansen FE, Jahnsen FL, et al. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 1998;42:635-42
   PubMed Web of Science ®Google Scholar
• Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352:1742-6
   PubMed Web of Science ®Google Scholar
• Binion DG, Rafiee P, Ramanujam KS, et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 2000;29:881-8
   PubMed Web of Science ®Google Scholar
• Binion DG, Fu S, Ramanujam KS, et al. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol 1998;275:G592-603
   Google Scholar
• Petersson J, Schreiber O, Steege A, et al. eNOS involved in colitis-induced mucosal blood flow increase. Am J Physiol Gastrointest Liver Physiol 2007;293:G1281-7
   Web of Science ®Google Scholar
• Cromer WE, Mathis JM, Granger DN, et al. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011;17:578-93
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Tsiolakidou G, Karmiris K, et al. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:515-23
   PubMed Web of Science ®Google Scholar
• Meucci G, Pareti F, Vecchi M, et al. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol 1999;34:287-90
   PubMed Web of Science ®Google Scholar
• D’Alessio S, Tacconi C, Fiocchi C, et al. Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol 2013;29:608-13
   PubMed Web of Science ®Google Scholar
• Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost 2014;12:1764-75
   PubMed Web of Science ®Google Scholar
• Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 2014;20:3180-90
   PubMed Web of Science ®Google Scholar
• Voudoukis E, Karmiris K, Oustamanolakis P, et al. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2013;25:1212-16
   PubMed Web of Science ®Google Scholar
• Kulnigg-Dabsch S, Schmid W, Howaldt S, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis 2013;19:1609-16
   PubMed Web of Science ®Google Scholar
• Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993;34:247-51
   PubMed Web of Science ®Google Scholar
• Andoh A, Yoshida T, Yagi Y, et al. Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol 2006;41:47-54
   PubMed Web of Science ®Google Scholar
• Schmid W, Vogelsang H, Papay P, et al. Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn’s disease. J Crohns Colitis 2014;8:495-503
   PubMed Web of Science ®Google Scholar
• Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-41
   PubMed Web of Science ®Google Scholar
• Tekelioğlu Y, Uzun H. Circulating platelet-leukocyte aggregates in patients with inflammatory bowel disease. J Chin Med Assoc 2013;76:182-5
   PubMed Web of Science ®Google Scholar
• Yan SL, Russell J, Granger DN. Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis 2014;20:353-62
   PubMed Web of Science ®Google Scholar
• Senchenkova EY, Komoto S, Russell J, et al. Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol 2013;183:173-81
   PubMed Web of Science ®Google Scholar
• Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014;111:570-4
   PubMed Web of Science ®Google Scholar
• Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30
   PubMed Web of Science ®Google Scholar
• Vrij AA, Rijken J, van Wersch JW, et al. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 2003;33:75-83
   PubMedGoogle Scholar
• Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738-42
   PubMed Web of Science ®Google Scholar
• Yoshida H, Yilmaz CE, Granger DN. Role of tumor necrosis factor-a in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis 2011;17:2217-23
   PubMed Web of Science ®Google Scholar
• Saibeni S, Saladino V, Chantarangkul V, et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010;125:278-82
   PubMed Web of Science ®Google Scholar
• Smith CJ, Haire WD, Kaufman SS, et al. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996;91:1221-5
   PubMed Web of Science ®Google Scholar
• Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995;7:1183-8
   PubMed Web of Science ®Google Scholar
• Alkim H, Ayaz S, Alkim C, et al. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost 2011;17:600-4
   PubMed Web of Science ®Google Scholar
• Stadnicki A. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol 2012;10:659-69
   PubMed Web of Science ®Google Scholar
• Rein-Smith CM, Church FC. Emerging pathophysiological roles for fibrinolysis. Curr Opin Hematol 2014;21:438-44
   PubMed Web of Science ®Google Scholar
• Zezos P, Papaioannou G, Nikolaidis N, et al. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis. Med Sci Monit 2009;15:563-72
   Web of Science ®Google Scholar
• Gris JC, Schved JF, Raffanel C, et al. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990;63:472-5
   PubMed Web of Science ®Google Scholar
• Saibeni S, Ciscato C, Vecchi M, et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006;4:1510-16
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Sfiridaki A, Tsiolakidou G, et al. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008;20:912-16
   PubMed Web of Science ®Google Scholar
• Owczarek D, Undas A, Foley JH, et al. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohns Colitis 2012;6:13-20
   PubMed Web of Science ®Google Scholar
• Owczarek D, Cibor D, Sałapa K, et al. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism. Inflamm Bowel Dis 2013;19:2616-24
   PubMed Web of Science ®Google Scholar
• Souto JC, Martínez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883-9
   PubMed Web of Science ®Google Scholar
• Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:953-62
   PubMed Web of Science ®Google Scholar
• Fumery M, Xiaocang C, Dauchet L, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 2014;8:469-79
   PubMed Web of Science ®Google Scholar
• Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012;55:1138-44
   PubMed Web of Science ®Google Scholar
• Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000;35:619-23
   PubMed Web of Science ®Google Scholar
• Vegh Z, Golovics PA, Lovasz BD, et al. Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort. Scand J Gastroenterol 2015;50:306-11
   PubMed Web of Science ®Google Scholar
• Isene R, Bernklev T, Høie O, et al. Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort. Scand J Gastroenterol 2014;49:820-5
   PubMed Web of Science ®Google Scholar
• Di Fabio F, Lykoudis P, Gordon PH. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. Semin Thromb Hemost 2011;37:220-5
   PubMed Web of Science ®Google Scholar
• Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53(4):542-8
   PubMed Web of Science ®Google Scholar
• Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657-63
   PubMed Web of Science ®Google Scholar
• Papay P, Miehsler W, Tilg H, et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis 2013;7:723-9
   PubMed Web of Science ®Google Scholar
• Scoville EA, Konijeti GG, Nguyen DD, et al. Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis 2014;20:631-6
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV, Tremaine WJ, et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013;173:743-52
   PubMed Web of Science ®Google Scholar
• Davies R, Galloway JB, Watson KD, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1831-4
   PubMed Web of Science ®Google Scholar
• Masson PL. Thromboembolic events and anti-tumor necrosis factor therapies. Int Immunopharmacol 2012;14:444-5
   PubMed Web of Science ®Google Scholar
• Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011;34:1173-84
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Petinaki E, Anagnostopoulou E, et al. Anticardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998;43:2507-12
   PubMed Web of Science ®Google Scholar
• Liang J, Wu S, Feng B, et al. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol 2011;46(10):1158-66
   PubMed Web of Science ®Google Scholar
• Zhong M, Dong XW, Zheng Q, et al. Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis. Thromb Res 2011;128:403-9
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Sfiridaki A, Tsiolakidou G, et al. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis 2007;13:410-15
   PubMed Web of Science ®Google Scholar
• Zintzaras E. Genetic variants of homocysteine/folate metabolism pathway and risk of inflammatory bowel disease: a synopsis and meta-analysis of genetic association studies. Biomarkers 2010;15:69-79
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Sargent M, Vos HL, et al. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol 2007;102:338-43
   PubMed Web of Science ®Google Scholar
• Reitsma PH. Genetics in thrombophilia. An update. Hamostaseologie 2014;35:47-51
   PubMed Web of Science ®Google Scholar
• Soria JM, Morange PE, Vila J, et al. Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc 2014;3:e001060
   Web of Science ®Google Scholar
• Alotaibi G, Alsaleh K, Wu C, et al. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Int Angiol 2014;33:301-8
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Cagan A, Gainer VS, et al. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:1905-10
   PubMed Web of Science ®Google Scholar
• Pleet JL, Vaughn BP, Morris JA, et al. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Aliment Pharmacol Ther 2014;39:940-8
   PubMed Web of Science ®Google Scholar
• Papa A, Papa V, Marzo M, et al. Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. Inflamm Bowel Dis 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Bernstein CN. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroenterol 2013;108:1486-95
   PubMed Web of Science ®Google Scholar
• Singh S, Kullo IJ, Pardi DS, et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 2015;12:26-35
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Deshpande AR, Pechman DM, et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011;106:741-7
   PubMed Web of Science ®Google Scholar
• Katsanos AH, Kosmidou M, Giannopoulos S, et al. Cerebral arterial infarction in inflammatory bowel diseases. Eur J Intern Med 2014;25:37-44
   PubMed Web of Science ®Google Scholar